Last reviewed · How we verify
NCT07226154: PRECEPT
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
trial testing Small RNA sequencing in Pancreatic Ductal Adenocarcinoma in 200 participants. Currently enrolling.
18 June 2026
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 November 2024 |
| Primary completion | 18 June 2026 |
| Estimated completion | 18 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Small RNA sequencing
- PRECEPT assay (qRT-PCR validation)
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
Sponsor
City of Hope Medical Center
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07226154
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Small RNA sequencing
Trials testing the same drug.
- NCT07225452 — An Exosomal miRNA-based Liquid Biopsy for ICC Detection · completed
- NCT06786273 — Time Course of Endometrium's Gene Expression Profiles Using Endometrial Tissue and Blood Samples · EARLY_PHASE1 · completed
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07226154 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07226154.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing